Skip to content
Search
Get in Touch
+49 941 2000 0890
info@2bind.com
Close
Open
Home
Careers
About us
Newsblog
Science and Publications
Contact Form
Shop
Compliance and Quality
Legal & Privacy
Our Services ›
Small Molecule Drug Discovery Services
Fragment-based Drug Discovery Services
Covalent Drug Discovery Services
PROTACs and Molecular Glues Services
RNA-targeted Drug Discovery Services
Antibody Lead Selection
Antibody Developability and Pre-Formulation Services
Characterization of Antibodies and Bispecifics
Biologics and Vaccines Services
Aptamer Discovery Services
Our Technologies ›
GCI
BLI
TRIC/MST
Spectral Shift
nanoDSF-DLS-PANTA
DLS
ITC
switchSENSE
kinFRET
FPS
SEC-MALS – HIC – IEX
RT-IC
Flow Cytometry
Stopped Flow
Close
Open
Home
Careers
About us
Newsblog
Science and Publications
Contact Form
Shop
Compliance and Quality
Legal & Privacy
Our Services ›
Small Molecule Drug Discovery Services
Fragment-based Drug Discovery Services
Covalent Drug Discovery Services
PROTACs and Molecular Glues Services
RNA-targeted Drug Discovery Services
Antibody Lead Selection
Antibody Developability and Pre-Formulation Services
Characterization of Antibodies and Bispecifics
Biologics and Vaccines Services
Aptamer Discovery Services
Our Technologies ›
GCI
BLI
TRIC/MST
Spectral Shift
nanoDSF-DLS-PANTA
DLS
ITC
switchSENSE
kinFRET
FPS
SEC-MALS – HIC – IEX
RT-IC
Flow Cytometry
Stopped Flow
2bind Newsblog
Newsblog
2024
2bind Opens New Headquarters
2bind GmbH Opens New Headquarters to as a Result of Quality Work and Continued Growth
Learn more
2023
Dr. Cosimo Kropp joins executive team as CBO
2bind GmbH Elevates Dr. Cosimo Kropp to Chief Business Officer
Learn more
Launch of Antibody Unit with Dr. Vera Molkenthin as Director
2bind GmbH Launches Antibody Unit with Appointment of Dr. Vera Molkenthin as Director
Learn more
2021
Appointment of Dr. Cosimo Kropp as Director Business Development
2bind GmbH Strengthens Business Development with Appointment of Dr. Cosimo Kropp
Learn more
2019
Appointment of Dr. Maximilian Plach as COO
2bind GmbH Appoints Dr. Maximilian Plach as COO to Oversee Rapid Growth
Learn more
2018
Service Partnership with Assay.Works
2bind GmbH and Assay.Works Join Forces to Expand Drug Discovery Services
Learn more
2017
Announcement of Dr. Maximilian Plach as CSO
2bind GmbH Appoints Dr. Maximilian Plach as CSO to Drive Biophysics in Drug Discovery
Learn more
Announcement of Dr. Thomas Schubert as CEO
2bind GmbH Appoints Dr. Thomas Schubert as CEO to Lead Strategic Shift Towards Drug Discovery Research Services .
Learn more
Founding of 2bind GmbH in the current form
2bind GmbH Relaunches with Renewed Focus on Empowering Drug Discovery through Biophysical Research Services.
Learn more
Get In Touch
+49 941 2000 0890
Customer Service
Im Gewerbepark D19a, 93059 Regensburg, Germany
Find us
How can we help you?
Quote Inquiry
Project Request
Technical Support
Other
Your Affiliation?
Company
University
Government Institution
Other
How did you find us?
Internet search
Social network (e.g. LinkedIn)
Recommendation
Conference/Meeting
Name
Email
Message
I consent to 2bind GmbH processing the information entered here in order to respond to my request. For more information please check out our detailed
privacy policy
.
Send Form ›
